• E-ISSN 2636-7688
  • Call Us: +90 422 341 06 60 / 1224
  • Email Us: dergi@inonu.edu.tr

Formerly Journal of Turgut Ozal Medical Center - ISSN 1300-1744

  • Annals of Medical Research



    Annals of Medical Research International Monthly Published Medical Journal

  • Annals of Medical Research

    In publication or citation search, the name similarities of the authors, typographical errors and institutional changes can cause confusion. To prevent this, researchers need to obtain a descriptive ID. ORCID (Open Researcher and Contributor ID) is a researcher-specific international URI with a 16-digit number. You can register for free for individual ORCID at http://orcid.org. Please indicate the ORCID number of all authors when submitting your article.

  • Annals of Medical Research


    Annals of Medical Research indexed in TÜBİTAK/ULAKBİM Tıp Veri Tabanı

  • Annals of Medical Research


    Annals of Medical Research indexed in

  • Annals of Medical Research
  • Annals of Medical Research
  • Annals of Medical Research
  • Annals of Medical Research

Dear readers,

Our journal is the official publication of Inonu University Medical Faculty and published uninterruptedly for 25 years. It was first published as the name of Inonu University Medical Journal and later as Journal of Turgut Ozal Medical Center. During its publication period, the journal accepted Turkish or English articles for publication.

Abstracting in an international index is just a paramount objective in the 25th year of the journal. Because of this goal, it was necessary to make a decision both in terms of journal name and publication language. It was important in this respect that the name of a general medical journal should be related to medicine again and it should be in English. For these reasons, the name of the journal was switched to Annals of Medical Research and its publication language is changed to in English. The logo of the journal was chosen as an apricot, which is the symbol of our city Malatya, the world capital of apricot. I hope the journal succeeds with its new name. Annals of Medical Research is It is published monthly.

Editor-in-Chief
Cuneyt Kayaalp

 

Retrospective evaluation of insulin degludec/insulin aspart co-formulation therapy in patients with type 2 Diabetes Mellitus: A single-center experience (p.1961-5)

Retrospective evaluation of insulin degludec/insulin aspart co-formulation therapy in patients with type 2 Diabetes Mellitus: A single-center experience (p.1961-5)

Ozlem Haliloglu1, Merve Korkmaz2, Ozge Polat Korkmaz1, Serdar Sahin1, Emre Durcan1,
Zeynep Osar Siva1
1Department of Internal Medicine, Division of Endocrinology-Metabolism and Diabetes, Cerrahpasa Medical Faculty, Istanbul University-Cerrahpasa, Istanbul, Turkey
2Department of Internal Medicine, Cerrahpasa Medical Faculty, Istanbul University-Cerrahpasa, Istanbul, Turkey

Copyright © 2020 by authors and Annals of Medical Research Publishing Inc.

Abstract

Aim: Insulin degludec/aspart (IDegAsp) co-formulation therapy is a novel drug in Turkey and the aim of this study was to retrospectively evaluate the effects of IDegAsp therapy on glycemic control and hypoglycemia in a single tertiary center in Turkey.
Material and Methods: The medical records of patients with type 2 diabetes mellitus, who were evaluated at diabetes clinic of Cerrahpaşa Medical Faculty between January and April 2018 and had started to use IDegAsp, were investigated. The demographic characteristics of the patients, anti-diabetic medications they were currently using, causes of treatment change, the IDegAsp doses, fasting blood glucose (FBG), HbA1c and hypoglycemic episodes at treatment onset, the third and sixth months of therapy were evaluated.
Results: Sixty-six patients (F/M:34/32; mean age:57.8±11,6years) were evaluated. Uncontrolled hyperglycemia (80.3%) and frequent hypoglycemic attacks (19,7%) were the causes of treatment change. IDegAsp was started as a single dose in 53% and double dose in 47% of patients. Sixty-two patients (93.9%) were using insulin and the number of injections were significantly reduced with IDegAsp (p0.001). There was no statistically significant difference in terms of insulin doses in sixth months of treatment (p=0.054), whereas FBG (p0.001), HbA1c (p0.001) levels and hypoglycemic attacks (p0.001) were reduced and the improvement in glycemic control occured particularly in the first 3 months of therapy.
Conclusion: Glycemic control and hypoglycemic episodes were improved and the number of daily injections decreased with 6-months of IDegAsp treatment. IDegAsp, which is a novel drug for our country, may increase the treatment compliance of the patients and thus facilitate reaching the glycemic targets.

 

Keywords: Glycemic control; hypoglycemia; insulin degludec/insulin aspart; type 2 diabetes mellitus

 

 

DOWNLOAD
doi: 10.5455/annalsmedres.2020.04.363      

DownloadXML


Contact us

+90 422 341 06 60 / 1224 - University

+90 422 341 06 60 Department


Location

Inonu University Faculty of Medicine

Malatya, 44069

Turkey


Send us email

dergi@inonu.edu.tr

dergi@inonu.edu.tr


demo

Annals of Medical Research is the scientific official journal of the Inonu University Faculty of Medicine. It is published monthly. The essential aim of the Annals of Medical Research is to publish scientifically high quality clinical and experimental research articles on fields of medicine which can contribute to the literature data. In addition, review articles, case reports, editorials, letters to the editors and manuscripts on publication ethics and medical history, which can contribute to the education and practices of physicians and health sector professionals within the scope of the journal’s target audience and which can increase the level of scientific communication between the authors and readers, are included in the scope of the journal.

 

Recent News

Links

Certificate of General Impact Factor

Email Newsletter

Sign up for the latest Inonu University Our new article, updates....